Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
about
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradationSingle-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescenceIn vivo analysis of Lrig genes reveals redundant and independent functions in the inner earCaenorhabditis elegans SMA-10/LRIG is a conserved transmembrane protein that enhances bone morphogenetic protein signalingLrig2-deficient mice are protected against PDGFB-induced gliomaCross-repressive interactions between Lrig3 and netrin 1 shape the architecture of the inner ear.Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3-dependent inner ear morphogenesis.Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling.The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressorThe LRIG family: enigmatic regulators of growth factor receptor signaling.The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.The epidermal growth factor receptor family: biology driving targeted therapeutics.Epiprofin orchestrates epidermal keratinocyte proliferation and differentiationNegative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing FieldLRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasiaLrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.LRIG and cancer prognosis.Negative regulation of ErbB family receptor tyrosine kinasesSenescent Atrophic Epidermis Retains Lrig1+ Stem Cells and Loses Wnt Signaling, a Phenotype Shared with CD44KO Mice.Skin stem cells: rising to the surface.LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.Mechanisms of ErbB receptor negative regulation and relevance in cancer.LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development.LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.Lrig1 is a cell-intrinsic modulator of hippocampal dendrite complexity and BDNF signaling.LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermisLrig1 Expression in Human Sebaceous Gland Tumors.Role of LIM kinases in normal and psoriatic human epidermis.The interfollicular epidermis of adult mouse tail comprises two distinct cell lineages that are differentially regulated by Wnt, Edaradd, and Lrig1.LRIG1 inhibits STAT3-dependent inflammation to maintain corneal homeostasis.A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity.Feedback regulation of RTK signaling in development.A protein interaction network centered on leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) regulates growth factor receptors.Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma.LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.Cardiac hypertrophy and decreased high-density lipoprotein cholesterol in Lrig3-deficient mice.
P2860
Q24563349-2E2F79F1-21A7-4301-BCFA-E495E7B53CE0Q24670890-CB937D47-6210-430A-A994-3DCFA56C2917Q27320101-64156799-A433-4CB1-BD0C-FB28E2B2A0AAQ27347461-DCCEFC0F-FF70-45AD-ABB0-66FD51CAF3B0Q28506352-2230C1F1-0F51-4367-8602-74BA08E12203Q30435788-7BC5F94E-399C-4FCF-8BC7-C9A428187F4DQ33529059-32656D09-76F5-4DAE-B2C1-CA0E3EDD1CC2Q34258498-B9839C28-5E8B-4806-8E0F-8F47351600C6Q34264864-0776D175-BB5E-47CB-AEA9-53CCC6A1A141Q34276176-4425715D-BA9E-4F74-B339-4017CB6C004BQ34345557-9115F4A5-5F56-417E-9C11-6F42244FDBA4Q34692233-ED7B5805-2850-4E21-BDD4-078A803C2501Q34698562-27228CE1-4EA5-429A-9510-7E570A407A18Q34996130-327DE556-5C9F-4F0E-8580-B274D243597BQ35141723-0292D040-F094-4BA4-A2EC-03D0E5C730D9Q35386137-99ED0003-C465-4634-A475-F39498905281Q35626430-ABAB2752-C84D-46F2-8F27-67959C04AE6BQ35634554-587C2804-504E-4841-81BB-4F2C25D04323Q36252667-0A99682A-9183-43B8-8F69-1B4B0DC4278DQ36404865-711D52EC-40CA-43A2-929A-31F6F48134C7Q36723368-31E68DBD-B1C2-4788-8601-27178BCCA76CQ37003688-E6766C6B-CE8F-45B5-9933-D70BEDA6CC19Q37109236-ACF46F10-8C40-404D-9D4D-64F2D7E68E63Q37244805-A7EE0BB8-0C51-4F76-A7AE-02080BA3313DQ37249599-B02384B8-6851-44C1-8BFE-730B6349823FQ38096295-B7EE410F-0377-4D6B-B284-FAB025BCF3A7Q38512194-FC4677A9-FDEC-441A-AF74-24833CB88FECQ39815152-5043DE63-EE8E-4598-822D-07F88152C1E2Q40231502-12F63FC0-7086-4C69-9CF3-64FC9444C666Q41390151-4AE59DDB-840A-4947-86EA-A2383268A1F6Q41966811-84CF7E49-40CD-4536-B3D0-B1A637FB881DQ42178016-B3615F31-1731-4B6E-BD8F-3AE963D65A33Q42445148-1AB879A2-72DC-4B62-AC08-A5FC8075752BQ42450624-AAC21366-96D3-4660-8BEF-E3E77EC5E52FQ42498384-820BE501-4D39-4172-B4DB-33AF8DF414BEQ46578462-5A750426-49F8-4B90-80D5-60B2EF4F64C7Q47215868-834AC463-AE18-409F-A6AC-F6BE54648810Q49390262-5193CA72-412B-4508-944D-0B23F6B67F13Q50047531-2607CB8A-469D-4D14-ABC2-4A2E14C3AC22Q50916387-89F804E3-C065-4875-ADF1-21A8300749ED
P2860
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
@ast
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
@en
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
@nl
type
label
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
@ast
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
@en
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
@nl
prefLabel
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
@ast
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
@en
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
@nl
P2093
P2860
P1433
P1476
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.
@en
P2093
Atsushi Tanemura
Aya Nakata
Gen Kondoh
Hiroyuki Miura
Kentaro Ozawa
Kinji Kobayashi
Kunihiko Yoshikawa
Masaya Tohyama
Satoshi Itami
Shigeki Inui
P2860
P356
10.1016/S0014-5793(02)02824-7
P407
P577
2002-06-01T00:00:00Z